Treatment of chronic gout in adult patients refractory to conventional therapy
Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).
Study Phase: | Phase 3 |
Location: | Chicago Clincal Research Institute, 611 W. Roosevelt Rd. Chicago, IL 60607 |
Study Category: | Cardiology |

Criteria
- Age 40 years or older
- Have previously experienced a heart attack, stroke, or reduced blood flow to limbs caused by narrowed arteries
- Currently receiving high-intensity statin (medication that lowers the level of harmful cholesterol in the blood)
Benefits
- You may be compensated for your time and travel